— Know what they know.
Not Investment Advice

LRMR NASDAQ

Larimar Therapeutics, Inc.
1W: -3.9% 1M: -23.5% 3M: -10.0% YTD: -14.7% 1Y: -28.7% 3Y: -34.1% 5Y: -76.2%
$2.96
-0.10 (-3.27%)
 
Weekly Expected Move ±10.0%
$2 $3 $3 $3 $4
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 29 · $307.5M mcap · 60M float · 2.94% daily turnover · Short 73% of daily vol
Smart Money Score
Bullish 75
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$307.5M
52W Range2.715-6.42
Volume834,959
Avg Volume1,763,996
Beta0.75
Dividend—
Analyst Ratings
8 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOCarole S. Ben-Maimon
Employees71
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-19
Three Bala Plaza East
Bala Cynwyd, PA 19004
US
844 511 9056
About Larimar Therapeutics, Inc.

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Recent Insider Trades

NameTypeSharesPriceDate
Harlow John B. Jr. A-Award 50,000 — 2026-09-29
Harlow John B. Jr. A-Award 800,000 $3.14 2026-09-29
Harlow John B. Jr. 0 — 2026-09-29
Hamilton Thomas Edwa P-Purchase 50,000 $3.34 2026-07-06
Hamilton Thomas Edwa A-Award 55,150 $3.33 2026-05-19

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms